Assay optimization and screening for measuring the kinetics of antibacterial resistance emergence

National Center For Advancing Translational Sciences

Investigators

Abstract

Antibiotic resistance is one of the major threats to public health today. To address this problem requires an urgent comprehensive approach. Strategic and multi-targeted combination therapy has been increasingly used clinically to treat bacterial infections. Collaborators at the FDA have developed a hollow-fibre infection model to assess the emergence of drug resistance in response to drug combinations (2 and 3 drugs), however, this is limited in its throughput. To address this, the projec team is leveraging NCATS's liquid handling capabilities to screen bacterial responses to combinations and measure the kinetics of the emergence of drug resistance.